Position in PTGX
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$20,902,831
+$2,566,288 QoQ
Shares Held
170,524
-2.0% QoQ
Ownership
0.264%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#52
of 343 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 6%
Shared 0%
None 94%
Common Shares in PTGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Fisher Asset Management, LLC holds $807,507,065 across 59 Biotechnology names. PTGX ranks #15 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
957,691 | $78,061,393 | |
| 2 | RCUS |
Arcus Biosciences, Inc.
|
2,139,396 | $65,957,578 | |
| 3 | CYTK |
Cytokinetics Inc
|
743,697 | $63,355,547 | |
| 4 | DNLI |
Denali Therapeutics Inc.
|
2,414,162 | $62,092,246 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
207,693 | $38,896,745 | |
| 6 | LGND |
Ligand Pharmaceuticals Inc
|
121,440 | $38,385,969 | |
| 7 | CLDX |
Celldex Therapeutics, Inc.
|
985,677 | $36,677,041 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
427,713 | $33,477,096 |
All Filings in PTGX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $20,902,831 | 170,524 | Shares | Defined | 2026-08-04 | |
| 2026-03-31 | $18,336,543 | 173,971 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $5,687,056 | 65,114 | Shares | Defined | 2026-02-09 | |
| No filing history on record for this holder in this stock. | ||||||